RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED AND REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug teclistamab tested for safety in Tough-to-Treat blood cancer
Disease control OngoingThis study tests the safety of teclistamab, a drug given as a shot, in 75 Indian adults with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see how safe it is in routine practice. Participants must have tried specific prior…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE4 • Sponsor: Johnson & Johnson Private Limited • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New universal CAR-T therapy targets tough multiple myeloma cases
Disease control TerminatedThis early-stage study tests a new type of CAR-T cell therapy, called UWD-00B, for people with multiple myeloma that has come back or not responded to other treatments. The therapy uses donor cells that are modified to target and kill cancer cells, and does not require the patien…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New cell therapy trial offers hope for Hard-to-Treat myeloma
Disease control OngoingThis early-phase study tests experimental cell therapies in 40 adults with relapsed and refractory multiple myeloma who have tried at least three prior treatments. The main goal is to check safety and find the right dose. While not a cure, it aims to control the disease and may l…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control OngoingThis phase 2 trial is testing a combination of four drugs—elotuzumab, pomalidomide, bortezomib, and dexamethasone—in 52 patients with multiple myeloma that has relapsed or stopped responding to at least two prior treatments. The goal is to see how many patients achieve a partial …
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug shows promise for Tough-to-Treat myeloma in Long-Term study
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug elranatamab in people with relapsed and refractory multiple myeloma, a type of blood cancer that has not responded to other treatments. The study tracks side effects like cytokine release syndrome and nerve-re…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody takes on Hard-to-Treat myeloma
Disease control OngoingThis early-stage trial is testing a drug called CLN-619 in 30 people with multiple myeloma that has come back or stopped responding to treatment. CLN-619 is an antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug …
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:50 UTC